Atrial flutter medical therapy

Jump to navigation Jump to search

Atrial flutter Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Atrial flutter from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

EKG Examples

Chest X Ray

Echocardiography

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

2015 ACC/AHA Guideline Recommendations

Acute Treatment of Atrial Flutter
Ongoing Management of Atrial Flutter

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Atrial flutter medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Atrial flutter medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Atrial flutter medical therapy

CDC on Atrial flutter medical therapy

Atrial flutter medical therapy in the news

Blogs on Atrial flutter medical therapy

Directions to Hospitals Treating Atrial flutter

Risk calculators and risk factors for Atrial flutter medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]

Overview

The management of atrial flutter is similar to that of atrial fibrillation with primary goals being control of ventricular rate, restoration of sinus rhythm, prevention of recurrent episodes and thromboembolic episodes. In the setting of unstable hemodynamics immediate electrical cardioversion is recommended. because of the high success rate and low complication rate radiofrequency ablation is considered superior to medical therapy in atrial flutter.

Medical Therapy

Management of Atrial Flutter in Emergency Department

Management of atrial flutter in emergency room depends on the hemodynamic state of the patient. Airway, breathing and circulation should be assessed first. Hemodynamically unstable patients are treated by electrical cardioversion initially. Ottawa Aggressive Protocol is a unique approach to cardioversion for ED patients with recent-onset episodes of atrial fibrillation and flutter. This approach is effective, safe and rapid and has the potential to reduce hospital admissions and expedite ED care[1]. Treatment options for atrial flutter in ED include:

  • Electric cardioversion
  • AV blocking agents and antiarrhythmic agents
  • Rapid atrial pacing

Electric Cardioversion

Synchronous direct current (DC) cardioversion is used as the initial treatment strategy in the management of hemodynamically unstable atrial flutter patients in ED. External electric cardioversion is effective in more than 90% of the cases and the initial shock strength used is 50 joules biphasic direct current. Sometimes the first shock may convert an atrial flutter to atrial fibrillation, in such cases a second shock preferable of a higher strength is usually given to restore sinus rhythm. Electric cardioversion increases the risk of stroke and hence pre-treatment with a blood thinner is advised if time permits.

AV Nodal Agents

Ventricular rate control is the prime goal in the management of atrial flutter. Drugs like calcium channel blockers (verapamil or diltiazem) or beta-blockers can be used for this. These drugs act as AV node blocking agents and control ventricular rate, thereby preventing tachycardia induced cardiomyopathy. Beta-blockers also have a direct antiarrhythmic effect on the atria. Administration of adenosine reveals flutter waves by blocking the AV node. History of Wolff-Parkinson-White syndrome or pre-excitation syndrome has to be ruled out before administrating, as these agents while acting on AV node can accelerate conduction in the accessory pathways and can precipitate ventricular fibrillation. Digoxin can also be used as an AV blocking agent in combination with calcium channel blockers and beta-blockers in the event of failure of electric cardioversion, atrial pacing and pharmacologic therapy.

Antiarrhythmic Agents

Class III agents like ibutilide, dofetilide, sotalol or amiodarone are typically used for pharmacologic cardioversion in the treatment of atrial flutter. Intravenous ibutilide is very effective in controlling acute atrial flutter episode and is found to be effective in at least 63% patients. Patients who are administered i.v ibutilide should be monitored using an EKG for at least 4 hrs after the infusion as ibutilide is known to cause QT prolongation and torsades de pointes.

Class IC agents like propafenone or flecainide have also shown to be effective in the conversion of acute onset atrial flutter to normal sinus rhythm.

References

  1. Stiell IG, Clement CM, Perry JJ; et al. (2010). "Association of the Ottawa Aggressive Protocol with rapid discharge of emergency department patients with recent-onset atrial fibrillation or flutter". CJEM. 12 (3): 181–91. PMID 20522282. Unknown parameter |month= ignored (help)

Template:WH Template:WS